[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100427509":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":41,"locations":51,"responsibleParty":68,"collaborators":70,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":24,"enrollmentInfo":82,"targetDuration":24,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":53,"whyStopped":24,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Turku University Hospital","OTHER_GOV",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"HGSOC patients treated with Neoadjuvant chemotherapy (NACT)","OTHER","Diagnostic laparoscopy followed with 3-4 cycles of platinum-taxane NACT and interval debulking surgery (IDS). Treatment response is monitored with FDG PET\u002FCT. IDS is followed by standard adjuvant therapy (ESGO\u002FESMO + local guidelines).\n\nDigital H\\&E slides and WGS, RNAseq are obtained from performed surgeries including relapse operations\u002Fascites drainages. Patients are followed with longitudinal ctDNA sampling.",[13,14,15],"Genetic: WGS and RNA sequencing","Genetic: circulating tumor DNA (ctDNA)","Diagnostic Test: FDG PET\u002FCT imaging",{"label":17,"type":10,"description":18,"interventionNames":19},"HGSOC patients treated with primary debulking surgery (PDS)","PDS is followed by standard adjuvant therapy (ESGO\u002FESMO + local guidelines). Digital H\\&E slides and WGS, RNAseq obtained from PDS and possible relapse operations\u002Fascites drainages when performed. Patients are followed with longitudinal ctDNA sampling.",[13,14,15],[21,26,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":24},"GENETIC","WGS and RNA sequencing",null,[9,17],{"type":22,"name":27,"description":24,"armGroupLabels":28,"otherNames":24},"circulating tumor DNA (ctDNA)",[9,17],{"type":30,"name":31,"description":24,"armGroupLabels":32,"otherNames":24},"DIAGNOSTIC_TEST","FDG PET\u002FCT imaging",[9,17],[34,38],{"name":35,"affiliation":36,"role":37},"Sampsa Hautaniemi, DTech, Prof","University of Helsinki","STUDY_DIRECTOR",{"name":39,"affiliation":5,"role":40},"Johanna Hynninen, MD, PhD","PRINCIPAL_INVESTIGATOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":24,"email":46},"Johanna Hynninen","CONTACT","+358 50 5383554","johanna.hynninen@utu.fi",{"name":48,"role":44,"phone":49,"phoneExt":24,"email":50},"Sampsa Hautaniemi","+358503364765","sampsa.hautaniemi@helsinki.fi",[52],{"facility":5,"status":53,"city":54,"state":24,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","Turku","20520","Finland","FI",{"type":59,"coordinates":60},"Point",[61,62],22.26869,60.45148,{"lat":62,"lon":61},[65,67],{"name":43,"role":44,"phone":66,"phoneExt":24,"email":46},"0505383554",{"name":39,"role":44,"phone":24,"phoneExt":24,"email":24},{"type":69,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[71],{"name":36,"class":10},"100427509","multi-layer-data-to-improve-diagnosis-predict-therapy-resistance-and-suggest-targeted-therapies-in-hgsoc-100427509",false,"NCT04846933","Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC","Integration of Multiple Data Levels to Improve Diagnosis, Predict Treatment Response and Suggest Targets to Overcome Therapy Resistance in High-grade Serous Ovarian Cancer","DECIDER","Inclusion Criteria:\n\n* Patients with a suspected ovarian cancer diagnosis treated at the Turku University Hospital\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Age \\\u003C18 years, too poor condition for active treatment (surgery, chemotherapy)\n* FDG PET\u002FCT scan is not performed for patients with diabetes mellitus and poor glucose balance.","FEMALE","18 Years",{"count":83,"type":84},200,"ESTIMATED","INTERVENTIONAL",[87],"NA","Chemotherapy resistance is the greatest contributor to mortality in advanced cancers and severe challenges remain in finding effective treatment modalities to cancer patients with metastasized and relapsed disease. High-grade serous ovarian cancer (HGSOC) is typically diagnosed at a stage where the disease is already widely spread to the abdomen and current standard of practice treatment consists of surgery followed by platinum-taxane based chemotherapy and maintenance therapy. While 90% of HGSOC patients show no clinically detectable signs of cancer after surgery and chemotherapy, only 43% of the patients are alive five years after diagnosis because of chemoresistant cancer.\n\nThis prospective, observational trial focuses on revealing major mechanisms causing chemoresistance in HGSOG patients and derive personalized treatment regimens for chemotherapy resistant HGSOC patients. The investigators recruit newly diagnosed advanced stage HGSOC patients who are then thoroughly followed during their cancer treatment. Longitudinal sampling includes digitalized H\\&E stained histology slides mainly collected during routine diagnostics, fresh tumor \\& ascites samples for next-generation sequencing\u002Fproteomics (WGS, RNA-seq, DNA-methylation, ATAC-seq, ChIP-seq, mass cytometry, etc.) and ex vivo experiments, plasma samples for circulating tumor DNA (ctDNA) analyses. Broad range of clinical parameters such as laboratory and radiologic parameters (e.g., FDG PET\u002FCT), given cancer treatments and their outcomes are collected. Radiomic analyses are performed to PET\u002FCT and CT scans. Long-term patient derived organoid lines are established from fresh tumor tissues. Actionable genomic alterations are searched.\n\nThe general objective is to establish a clinically useful precision oncology approach based on multi-level data collected in longitudinal setting, and translate the most potent and validated discoveries into clinical use. DECIDER project will produce AI-powered diagnostic tools, cutting-edge software platforms for clinical decision-making, novel data analysis \\& integration methods, and high-throughput ex vivo drug screening approaches.",[90,91],"High Grade Ovarian Serous Adenocarcinoma","High Grade Serous Carcinoma",[93,94,95,96,97,98,99,100,101,102,103,104,105,106],"chemoresistance","personalized medicine","WGS","ctDNA","digital pathology","FDG PET\u002FCT","bioinformatics","AI","ovarian cancer","tumor evolution","artificial intelligence","organoid","DNA methylation","radiomics","2025-01-14",{"date":109,"type":110},"2025-01-16","ACTUAL",{"date":112,"type":110},"2012-02-01",{"date":114,"type":84},"2029-12",{"name":5,"class":6},1]